Veru logo

VeruNASDAQ: VERU

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 February 1999

Next earnings report:

07 February 2025

Last dividends:

28 April 2014

Next dividends:

N/A
$93.67 M
-95%vs. 3y high
44%vs. sector
-vs. 3y high
-vs. sector
-84%vs. 3y high
64%vs. sector
-81%vs. 3y high
67%vs. sector

Price

after hours | Fri, 15 Nov 2024 00:17:10 GMT
$0.64+$0.01(+2.38%)

Dividend

No data over the past 3 years
$3.95 M$3.56 M
$3.95 M-$10.97 M

Analysts recommendations

Institutional Ownership

VERU Latest News

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
globenewswire.com05 November 2024 Sentiment: POSITIVE

MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
globenewswire.com21 October 2024 Sentiment: POSITIVE

MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas.

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
globenewswire.com16 October 2024 Sentiment: POSITIVE

MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the World Obesity and Weight Management Congress, taking place October 24-26, 2024, in Baltimore, Maryland.

Veru to Present at the 2024 Cantor Global Healthcare Conference
globenewswire.com11 September 2024 Sentiment: POSITIVE

MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present a corporate update with a focus on the progress of Veru's Phase 2b clinical development program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the 2024 Cantor Global Healthcare Conference on September 18th at 1:55 PM – 2:25 PM Eastern Time.

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: NEUTRAL

Veru Inc. (NASDAQ:VERU ) Q3 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Officer Michele Greco - Chief Financial Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies William Wood - B. Riley Securities Gary Nachman - Raymond James Leland Gershell - Oppenheimer Yi Chen - H.C.

Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: POSITIVE

Veru Inc. (VERU) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.13 per share a year ago.

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
globenewswire.com08 August 2024 Sentiment: POSITIVE

--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected January 2025--

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
globenewswire.com01 August 2024 Sentiment: POSITIVE

MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, August 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 third quarter financial results and to provide a business update.

Veru to Participate in the BTIG Virtual Biotechnology Conference
globenewswire.com29 July 2024 Sentiment: POSITIVE

MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in one-on-one meetings with investors at the BTIG Virtual Biotechnology Conference on August 5th, 2024.

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
globenewswire.com24 June 2024 Sentiment: POSITIVE

MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.

  • 1(current)

What type of business is Veru?

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

What sector is Veru in?

Veru is in the Healthcare sector

What industry is Veru in?

Veru is in the Biotechnology industry

What country is Veru from?

Veru is headquartered in United States

When did Veru go public?

Veru initial public offering (IPO) was on 11 February 1999

What is Veru website?

https://verupharma.com

Is Veru in the S&P 500?

No, Veru is not included in the S&P 500 index

Is Veru in the NASDAQ 100?

No, Veru is not included in the NASDAQ 100 index

Is Veru in the Dow Jones?

No, Veru is not included in the Dow Jones index

When was Veru the previous earnings report?

No data

When does Veru earnings report?

The next expected earnings date for Veru is 07 February 2025